GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for ONTARGET

ONTARGET

Official Title

ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for CV Events.

Status

Completed

Overview

To determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of CV death, MI, stroke or hospitalization for CHF compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.

Study Design

Randomized, double-blind, parallel group design.

Primary Endpoint

Cardiovascular death Non-fatal myocardial infarction Non-fatal stroke Hospitalization for congestive heart failure. Secondary endpoints: Newly diagnosed CHF. CV revascularization procedures. Newly diagnosed diabetes. Cognitive decline (adjudication done by a special committee). New onset of atrial fibrillation. Nephropathy. All primary and secondary endpoints were adjudicated.

Number of Patients

25925

Number of Sites

733

Number of Countries

40

Study Period

2002–2010

Principal Investigator

Salim Yusuf

Program Manager

Koon Teo

Research Coordinator

Ingrid Copland

Key Publications

  • The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
  • Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.
  • The Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.